Rebrain services provide precise brain targeting for DBS neurosurgery, enhancing patient outcomes in Parkinson’s disease and Essential Tremor treatments

RebrAIn’s news

Back to Resources

Biotech Finances Highlights RebrAIn’s Successful Funding Round for supervised AI Neurosurgery

We are pleased to announce that Biotech Finances has featured RebrAIn in their recent article. RebrAIn has successfully completed a €3.7 million funding round led by Karista, with participation from Nouvelle Aquitaine Co-Investissement and existing investors.

Our CE-marked and FDA-cleared SaaS solution revolutionizes neurosurgical procedures by using advanced AI algorithms and MRI sequences to provide optimal targets for electrode placement in Deep Brain Stimulation (DBS) surgeries. The funds will support team expansion and international commercialization of our precision AI-driven neurosurgery solutions.

Read the article, in french, here.

An English translation by Google is available here.

Back to Resources

Our latest public updates

From Patient to Practice: RebrAIn Wins the Resah Tender

From Patient to Practice: RebrAIn Wins the Resah Tender

Mar 19, 2025

The Strategic Importance of This Tender This success marks a major strategic turning point for RebrAIn, as the Resah procurement center plays a key role in the public healthcare sector in France. By enabling the member hospitals to choose the most effective...

RebrAIn Hosts Inaugural Medical Advisory Board Meeting (MAB)

RebrAIn Hosts Inaugural Medical Advisory Board Meeting (MAB)

Oct 1, 2024

RebrAIn recently held the inaugural meeting of its Medical Advisory Board (MAB), marking a significant milestone in the company’s ongoing mission to deliver transformative AI-powered tools to neurosurgeons. The meeting also underscored RebrAIn's pivotal role in...